Titan Pharmaceuticals (NSDQ:TTNP) has treated the first patient in a Phase I/II trial of its ropinirole implant designed to treat the signs and symptoms of idiopathic Parkinson’s disease.
Ropinirole is a dopamine agonist traditionally given orally to patients with Parkinson’s disease or restless leg syndrome. Titan’s ropinirole implant uses the company’s ProNeura drug delivery tech to continuously deliver ropinirole HCl.
Get the full story at our sister site, Drug Delivery Business News.
The post Titan Pharmaceuticals treats first Parkinson’s patient with subdermal implant appeared first on MassDevice.